UNSPSC 51381510: Flufenamic acid

This classification denotes an anti-inflammatory agent with the molecular formula C14H10F3NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 60GCX7Y6BH, chemically known as n-(alpha,alpha,alpha-trifluoro-m-tolyl)anthranilic acid but generally known as flufenamic acid, which bears US NIH Compound Identifier 3371. European Medicines Agency schedules Flufenamic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07686MIG.

World Health Organization schedules flufenamic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule flufenamic acid under HS 29224995 and SITC 51465. As of Q4 2014, FLUFENAMIC ACID remains the US FDA Preferred Term for this commodity. SMILES: FC(F)(F)C1CC(NC2C(CCCC2)C(=O)O)CCC1.

UNSPSC 51381510 Flufenamic acid is a Commodity code that shows minimal alignment with actual state and local procurement activity. The single recent opportunity in the dataset—Seminole County, Florida's IFB 60459723LAS for naloxone and drug deactivation systems—bears no relationship to flufenamic acid, a nonsteroidal anti-inflammatory drug. The mismatch suggests this code either receives sparse tagging in state and local systems or is misapplied to health and safety procurement that falls outside the pharmaceutical active-ingredient scope the code nominally describes. State and local governments do procure pharmaceuticals and medical supplies, but this particular code shows no evidence of supporting that activity in current procurement records.

Seminole County's naloxone and drug deactivation system solicitation, posted June 30, 2026 with a July 26, 2023 response date (reflecting apparent data-entry inconsistencies in the source record), sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The IFB required electronic submission, included drug-free workplace and E-Verify compliance, and specified a two-year initial term with one-year renewal option. FEMA funding was cited, introducing federal compliance overlays including the Clean Air Act and Federal Water Pollution Control Act. No explicit set-asides for disadvantaged enterprises were designated, and pricing was to be fixed-fee with all shipping and delivery costs included in vendor proposals. The absence of broader activity under this code in current state and local records suggests limited pursuit opportunity unless pharmaceutical procurement patterns shift or the code tagging in state systems becomes more precise.